Nvidia-backed AI drug discovery company Iambic (IAM.US) files for U.S. IPO to advance three early-stage cancer drugs.

Zhito Finance APP has learned that Iambic Therapeutics Inc., a clinical-stage life sciences and technology company backed by Nvidia (NVDA.US), has applied for an initial public offering (IPO) in the United States. According to its filing submitted to the U.S. Securities and Exchange Commission (SEC) on Monday, the San Diego-based company uses artificial intelligence (AI) to develop new therapies and plans to use the IPO proceeds to advance three early-stage cancer drugs.